Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Ovarian Neoplasms 3168Uterine Cervical Neoplasms 2191Endometrial Neoplasms 1334Breast Neoplasms 819Fallopian Tube Neoplasms 808Carcinoma, Ovarian Epithelial 772Neoplasms 540Colorectal Neoplasms 439Carcinoma, Non-Small-Cell Lung 420Uterine Cervical Dysplasia 376Pancreatic Neoplasms 363Stomach Neoplasms 354Prostatic Neoplasms 318Lung Neoplasms 315Melanoma 289Uterine Neoplasms 239Peritoneal Neoplasms 238Neoplasm Metastasis 238Vulvar Neoplasms 229Urinary Bladder Neoplasms 225Esophageal Neoplasms 225Head and Neck Neoplasms 222Sarcoma 219Carcinoma, Renal Cell 214Recurrence 213Colonic Neoplasms 210Papillomavirus Infections 206Triple Negative Breast Neoplasms 191Squamous Cell Carcinoma of Head and Neck 177Vaginal Neoplasms 147

Interventions

Itraconazole 1Hydroxychloroquine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Platinum-resistant Epithelial Ovarian Cancer × Gynecologic × Clear all
NCT05243524 2023-09-13

AVALON

ImmunoVaccine Technologies, Inc. (IMV Inc.)

Phase 2 Terminated
16 enrolled
Gynecologic

Platinum-resistant Epithelial Ovarian Cancer

NCT03081702 2021-04-02

A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer

University Health Network, Toronto

Phase 1/2 Completed
13 enrolled
Gynecologic

Platinum-resistant Epithelial Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡